ONO PHARMACEUTICAL CO.,LTD.

May 22, 2019

Array BioPharma Announces BRAFTOVI + MEKTOVI + Cetuximab Meet Primary Endpoints of ORR and OS in Phase 3 BEACON CRC Trial Interim Analysis for the Treatment of BRAF^{V600E}-mutant Metastatic Colorectal Cancer

This information is intended to notify the press release issued on May 21 (ET) by Array BioPharma Inc. Please click http://www.arraybiopharma.com/ for the original press release distributed by Array.

(1st paragraph of the press release)

Boulder, Colo. (May 21, 2019) – Array BioPharma Inc. (Nasdaq: ARRY) today announced positive results from the interim analysis of the Phase 3 BEACON CRC trial evaluating the combination of BRAFTOVI® (encorafenib), a BRAF inhibitor, MEKTOVI® (binimetinib), a MEK inhibitor and ERBITUX® (cetuximab), an anti-EGFR antibody (BRAFTOVI Triplet), in patients with BRAF^{V600E}-mutant metastatic colorectal cancer (mCRC), following one or two prior lines of therapy. The trial met both primary endpoints of confirmed objective response rate (ORR), as assessed by Blinded Independent Central Review (BICR), and overall survival (OS). Array intends to submit the results of the BEACON CRC trial for marketing approval in the second half of 2019.

About the Ono and Array BioPharma Collaboration

In May 2017, Ono Pharmaceutical Co., Ltd. ("ONO") entered into the license agreement with Array BioPharma Inc. regarding BRAFTOVI® (encorafenib), a BRAF inhibitor and MEKTOVI® (binimetinib), a MEK inhibitor and received rights to develop and commercialize both products in Japan and South Korea.

About the Development Status of BRAFTOVI® and MEKTOVI®

In January 2019, ONO received the manufacturing and marketing approvals for BRAFTOVI® and MEKTOVI® and launched them for the indication of unresectable BRAF-mutant melanoma in Japan in February 2019. The products are currently in two global Phase 3 clinical trials for the treatment of patients with BRAF-mutant melanoma (COLUMBUS study) and BRAF-mutant colorectal cancer (BEACON CRC study) as a combination therapy.

Contacts:
ONO PHARMACEUTICAL CO., LTD.
Corporate Communications
public_relations@ono.co.jp